
Boston Scientific Stock
Innovator of medical solutions that improve the health
Sign up today and learn more about Boston Scientific Stock
Invest in or value your shares in one or many pre-IPO companies through an EquityZen investment vehicle.
About Boston Scientific Stock
Boston Scientific is a leading innovator of medical solutions that improve the health of patients around the world. Boston Scientific's products and technologies are used to diagnose or treat a wide range of medical conditions, including heart, digestive, pulmonary, vascular, urological, women's health and chronic pain conditions. Boston Scientific's journey of innovation began in 1979, when their revolutionary steerable catheters were first used in less-invasive procedures. Today, Boston Scientific continues their legacy of delivering meaningful innovation to meet patient needs around the world and deliver economic value to their customers. Boston Scientific has advanced the practice of less-invasive medicine by providing a broad and deep portfolio of innovative products, technologies and services across a wide range of medical specialties. These less-invasive medical technologies provide alternatives to major surgery and other medical procedures that are typically traumatic to the body. In less-invasive procedures, devices are usually inserted into the body through natural openings or small incisions and can be guided to most areas of the anatomy to diagnose and treat a wide range of medical problems. Boston Scientific continues to innovate in these areas and are extending their innovations into new geographies and high-growth adjacency markets. Boston Scientific is dedicated to transforming lives through innovative medical solutions that improve the health of patients around the world. Boston Scientific acts with integrity and compassion to support patients, customers, our communities and each other. Boston Scientific fosters an environment of creativity to transform new ideas into breakthrough services and solutions that create value for patients, customers and employees. Boston Scientific strives for high performance to benefit their patients, clinicians and shareholders and they work collaboratively to pursue global opportunities that extend the reach of their medical solutions.
Funding History
February 2018 | $1.0B |
---|
Management
President & CEO
Michael Mahoney
Press
Forbes - Apr, 2 2020
Ride Intuitive Surgical Over Boston Scientific In The Current Crisis?Forbes - Mar, 9 2020
How Does Boston Scientific Get To $12 Billion Sales In 2020: Rhythm & Neuro Or Cardiovascular?New York Times - Dec, 13 2019
To Prevent Deadly Infections, F.D.A. Approves the First Disposable ‘Scope’Forbes - Nov, 22 2019
What’s Boston Scientific’s Fair Stock Price Estimate Based On Expected 2020 Earnings?Forbes - Oct, 4 2019
How Much Can Boston Scientific Revenues Grow Over The Next Three Years?Forbes - Jul, 3 2019
How Does Medtronic's Diabetes Care Business Compare To Its Peers?New York Times - Jun, 14 2019
Women Who Sued Makers of Pelvic Mesh Are Suing Their Own Lawyers, TooWall Streets Journal - May, 17 2019
Gormley’s Take: Vertiflex’s Path to Acquisition Shows Opportunities, Hurdles for Orthopedic StartupsWall Streets Journal - Apr, 16 2019
FDA Orders Makers of Women’s Surgical Mesh to Stop Selling the Productsmiamiherald - Feb, 18 2019
Medtronic says deaths omitted from analysis of paclitaxel-coated devicejpost - Feb, 17 2019
Virtual scalpel, please: Israeli tech revolutionizes the operating theatercnbc - Feb, 16 2019
Controversy, dissent and baggage are good for your stock portfoliofiercebiotech - Feb, 15 2019
FTC requests additional info from Boston Scientific and BTG ahead of $4.2B mergermassdevice - Feb, 12 2019
Boston Scientific launches AdVance XP male stress urinary incontinence slingWall Streets Journal - Feb, 12 2019
FDA Panel Assesses Risks of Women’s Surgical Meshmassdevice - Feb, 12 2019
Boston Scientific launches AdVance XP male stress urinary incontinence slingfiercebiotech - Feb, 8 2019
Boston Scientific redesigns, upsizes mesh sling system for men with stress urinary incontinencestartribune - Feb, 6 2019
Boston Scientific shares rise nearly 3 percent after earnings beat expectationsEquityZen does not have an affiliation with, formal relationship with, or endorsement from any companies featured above. This profile is based on publicly available information and is intended to be informative in nature.
Some data provided by Crunchbase